Trial Profile

Dose finding study of the combination chemotherapy consisting of irinotecan hydrochloride and pegylated liposomal doxorubicin combination therapy in patients with recurrent ovarian cancer (Phase I trial).

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 12 May 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 May 2012 Status changed from active, no longer recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
13 Mar 2012 Status changed from suspended to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
23 Dec 2011 Status changed from recruiting to suspended as reported by University Hospital Medical Information Network - Japan.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com